{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:29:43Z","timestamp":1789475383489,"version":"build-2803163510"},"reference-count":55,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1097\/01.iae.0000244659.62202.ee","type":"journal-article","created":{"date-parts":[[2007,1,11]],"date-time":"2007-01-11T04:17:34Z","timestamp":1168489054000},"page":"1-7","source":"Crossref","is-referenced-by-count":68,"title":["MOLECULAR PATHOLOGY OF EYES WITH VON HIPPEL\u2013LINDAU (VHL) DISEASE"],"prefix":"10.1097","volume":"27","author":[{"given":"CHI-CHAO","family":"CHAN","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ATIF BEN DANIEL","family":"COLLINS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EMILY Y.","family":"CHEW","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210130","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(03)13643-4","article-title":"von Hippel-Lindau disease.","volume":"361","author":"Lonser","year":"2003","journal-title":"Lancet"},{"key":"R2-1-20210130","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0039-6257(01)00245-4","article-title":"von Hippel-Lindau disease.","volume":"46","author":"Singh","year":"2001","journal-title":"Surv Ophthalmol"},{"key":"R3-1-20210130","first-page":"367","article-title":"Von-Hippel-Lindau disease: the recognition and treatment of early angiomatosis retinae and the use of cryosurgery as an adjunct to therapy.","volume":"68","author":"Welsh","year":"1970","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R4-1-20210130","first-page":"495","article-title":"Ocular manifestations of von Hippel-Lindau disease: clinical and genetic investigations.","volume":"103","author":"Chew","year":"2005","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R5-1-20210130","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1126\/science.8493574","article-title":"Identification of the von Hippel-Lindau disease tumor suppressor gene.","volume":"260","author":"Latif","year":"1993","journal-title":"Science"},{"key":"R6-1-20210130","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/332268a0","article-title":"Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma.","volume":"332","author":"Seizinger","year":"1988","journal-title":"Nature"},{"key":"R7-1-20210130","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1073\/pnas.68.4.820","article-title":"Mutation and cancer: statistical study of retinoblastoma.","volume":"68","author":"Knudson","year":"1971","journal-title":"Proc Natl Acad Sci USA"},{"key":"R8-1-20210130","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrc885","article-title":"Molecular basis of the VHL hereditary cancer syndrome.","volume":"2","author":"Kaelin","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"R9-1-20210130","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semcancer.2003.09.019","article-title":"Multiple regulatory pathways of vascular permeability factor\/vascular endothelial growth factor (VPF\/VEGF) expression in tumors.","volume":"14","author":"Mukhopadhyay","year":"2004","journal-title":"Semin Cancer Biol"},{"key":"R10-1-20210130","doi-asserted-by":"crossref","first-page":"H2528","DOI":"10.1152\/ajpheart.01077.2005","article-title":"Hypoxia and hypoxia-inducible factor-1{alpha} promote growth factor-induced proliferation of human vascular smooth muscle cells.","volume":"290","author":"Schultz","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R11-1-20210130","first-page":"1109","article-title":"Inhibition of angiogenic activity of renal carcinoma by an antisense oligonucleotide targeting fibroblast growth factor-2.","volume":"25","author":"Cenni","year":"2005","journal-title":"Anticancer Res"},{"key":"R12-1-20210130","doi-asserted-by":"crossref","first-page":"C172","DOI":"10.1152\/ajpcell.00284.2005","article-title":"Thrombin induces expression of FGF-2 via activation of PI3K-Akt-Fra-1 signaling axis leading to DNA synthesis and motility in vascular smooth muscle cells.","volume":"290","author":"Cao","year":"2006","journal-title":"Am J Physiol Cell Physiol"},{"key":"R13-1-20210130","first-page":"2251","article-title":"Third International Meeting on von Hippel-Lindau disease.","volume":"59","author":"Zbar","year":"1999","journal-title":"Cancer Res"},{"key":"R14-1-20210130","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/00005792-199711000-00001","article-title":"von Hippel-Lindau disease.","volume":"76","author":"Maher","year":"1997","journal-title":"Medicine (Baltimore)"},{"key":"R15-1-20210130","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/(SICI)1098-1004(1996)8:4<348::AID-HUMU8>3.0.CO;2-3","article-title":"Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan.","volume":"8","author":"Zbar","year":"1996","journal-title":"Hum Mutat"},{"key":"R16-1-20210130","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0065-230X(01)82003-0","article-title":"Von Hippel-Lindau disease: clinical and molecular perspectives.","volume":"82","author":"Clifford","year":"2001","journal-title":"Adv Cancer Res"},{"key":"R17-1-20210130","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1001\/archopht.117.3.371","article-title":"Clinical characteristics of ocular angiomatosis in von Hippel-Lindau disease and correlation with germline mutation.","volume":"117","author":"Webster","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"R18-1-20210130","first-page":"3067","article-title":"Retinal hemangioblastoma in von Hippel-Lindau disease: a clinical and molecular study.","volume":"43","author":"Dollfus","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R19-1-20210130","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/S0161-6420(83)34389-X","article-title":"Presumed acquired retinal hemangiomas.","volume":"90","author":"Shields","year":"1983","journal-title":"Ophthalmology"},{"key":"R20-1-20210130","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1016\/S0161-6420(00)00422-X","article-title":"Juxtapapillary capillary hemangiomas. Clinical features and visual acuity outcomes.","volume":"107","author":"McCabe","year":"2000","journal-title":"Ophthalmology"},{"key":"R21-1-20210130","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00417-004-0908-9","article-title":"A clinicopathologic case report on macular hole associated with von Hippel-Lindau disease: a novel ultrastructural finding of wormlike, wavy tangles of filaments.","volume":"242","author":"Inoue","year":"2004","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R22-1-20210130","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.optm.2005.06.011","article-title":"Juxtapapillary hemangioma: a case report and review of clinical features and management of von Hippel-Lindau disease.","volume":"76","author":"Aumiller","year":"2005","journal-title":"Optometry"},{"key":"R23-1-20210130","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/archopht.117.5.625","article-title":"VHL gene deletion and enhanced VEGF gene expression detected in the stromal cells of retinal angioma.","volume":"117","author":"Chan","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"R24-1-20210130","first-page":"75","article-title":"von Hippel-Lindau gene deletion and expression of hypoxia-inducible factor and ubiquitin in optic nerve hemangioma.","volume":"102","author":"Chan","year":"2004","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R25-1-20210130","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0046-8177(97)90075-7","article-title":"von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease.","volume":"28","author":"Vortmeyer","year":"1997","journal-title":"Hum Pathol"},{"key":"R26-1-20210130","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/0046-8177(94)90044-2","article-title":"Hemangioblastoma of the optic nerve.","volume":"25","author":"Rubio","year":"1994","journal-title":"Hum Pathol"},{"key":"R27-1-20210130","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0002-9394(76)90418-9","article-title":"Light and electron microscopic study of early lesions in angiomatosis retinae.","volume":"82","author":"Nicholson","year":"1976","journal-title":"Am J Ophthalmol"},{"key":"R28-1-20210130","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0161-6420(92)32024-X","article-title":"Retinal hemangioblastoma: a histologic, immunohistochemical, and ultrastructural evaluation.","volume":"99","author":"Grossniklaus","year":"1992","journal-title":"Ophthalmology"},{"key":"R29-1-20210130","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/0002-9394(68)91292-0","article-title":"Von Hippel-Lindau disease. Histopathologic findings in a treated and an untreated eye.","volume":"66","author":"Goldberg","year":"1968","journal-title":"Am J Ophthalmol"},{"key":"R30-1-20210130","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s004170050271","article-title":"Morphologic and genetic analysis of retinal angioma associated with massive gliosis in a patient with von Hippel-Lindau disease.","volume":"237","author":"Vortmeyer","year":"1999","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R31-1-20210130","first-page":"697","article-title":"Expression of stem cells markers in ocular hemangioblastoma associated with von Hippel-Lindau (VHL) disease.","volume":"11","author":"Chan","year":"2005","journal-title":"Mol Vis"},{"key":"R32-1-20210130","first-page":"7051","article-title":"Developmental arrest of angioblastic lineage initiates tumorigenesis in von Hippel-Lindau disease.","volume":"63","author":"Vortmeyer","year":"2003","journal-title":"Cancer Res"},{"key":"R33-1-20210130","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3171\/jns.2005.102.3.0503","article-title":"Tumors of the endolymphatic sac in patients with von Hippel-Lindau disease: implications for their natural history, diagnosis, and treatment.","volume":"102","author":"Kim","year":"2005","journal-title":"J Neurosurg"},{"key":"R34-1-20210130","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1210\/jc.2004-1899","article-title":"Differential expression of erythropoietin and its receptor in von Hippel-Lindau-associated and MEN type 2-associated pheochromocytomas.","volume":"90","author":"Vogel","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R35-1-20210130","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/ana.20090","article-title":"Developmental effects of von Hippel-Lindau gene deficiency.","volume":"55","author":"Vortmeyer","year":"2004","journal-title":"Ann Neurol"},{"key":"R36-1-20210130","first-page":"S358","article-title":"Neovascularization in Von Hippel-Lindau disease: Absence of vascular endothelial growth factor in vitreous specimens.","volume":"41","author":"Kinyoun","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R37-1-20210130","doi-asserted-by":"crossref","first-page":"10595","DOI":"10.1073\/pnas.93.20.10595","article-title":"Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.","volume":"93","author":"Iliopoulos","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"R38-1-20210130","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1182\/blood.V92.9.3388","article-title":"Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function.","volume":"92","author":"Krieg","year":"1998","journal-title":"Blood"},{"key":"R39-1-20210130","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/sj.embor.7400377","article-title":"VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1alpha.","volume":"6","author":"Li","year":"2005","journal-title":"EMBO Rep"},{"key":"R40-1-20210130","doi-asserted-by":"crossref","first-page":"5629","DOI":"10.1128\/MCB.17.9.5629","article-title":"The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity.","volume":"17","author":"Mukhopadhyay","year":"1997","journal-title":"Mol Cell Biol"},{"key":"R41-1-20210130","first-page":"1358","article-title":"Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas.","volume":"55","author":"Wizigmann-Voos","year":"1995","journal-title":"Cancer Res"},{"key":"R42-1-20210130","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-06-2284","article-title":"Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells.","volume":"107","author":"Hess","year":"2006","journal-title":"Blood"},{"key":"R43-1-20210130","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1634\/stemcells.2004-0232","article-title":"Somatic stem cell marker prominin-1\/CD133 is expressed in embryonic stem cell-derived progenitors.","volume":"23","author":"Kania","year":"2005","journal-title":"Stem Cells"},{"key":"R44-1-20210130","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3109\/10428199809057558","article-title":"Expression of the c-kit (CD117) molecule in normal and malignant hematopoiesis.","volume":"30","author":"Escribano","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"R45-1-20210130","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1182\/blood.V81.9.2223.2223","article-title":"Structure, function, and activation of the erythropoietin receptor.","volume":"81","author":"Youssoufian","year":"1993","journal-title":"Blood"},{"key":"R46-1-20210130","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1093\/carcin\/bgg060","article-title":"Erythropoietin regulates tumour growth of human malignancies.","volume":"24","author":"Yasuda","year":"2003","journal-title":"Carcinogenesis"},{"key":"R47-1-20210130","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1158\/1078-0432.1059.11.3","article-title":"Coexpression of erythropoietin and erythropoietin receptor in von Hippel-Lindau disease-associated renal cysts and renal cell carcinoma.","volume":"11","author":"Lee","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R49-1-20210130","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature01874","article-title":"Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL.","volume":"425","author":"Staller","year":"2003","journal-title":"Nature"},{"key":"R50-1-20210130","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jama.291.8.943","article-title":"Antiangiogenic therapy for von Hippel-Lindau disease.","volume":"291","author":"Madhusudan","year":"2004","journal-title":"JAMA"},{"key":"R51-1-20210130","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1097\/01.ASN.0000091589.10594.66","article-title":"Targeting of the VHL-hypoxia-inducible factor-hypoxia-induced gene pathway for renal cell carcinoma therapy.","volume":"14","author":"Sosman","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"R52-1-20210130","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1040-8428(02)00076-8","article-title":"Renal cell carcinoma: current status and future directions.","volume":"45","author":"Martel","year":"2003","journal-title":"Crit Rev Oncol Hematol"},{"key":"R53-1-20210130","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0161-6420(02)01159-4","article-title":"Rapid and durable recovery of visual function in a patient with von Hippel-Lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416.","volume":"109","author":"Aiello","year":"2002","journal-title":"Ophthalmology"},{"key":"R54-1-20210130","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0002-9394(03)00101-6","article-title":"Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas.","volume":"136","author":"Girmens","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"R55-1-20210130","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1210\/me.2002-0438","article-title":"Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells.","volume":"17","author":"Hall","year":"2003","journal-title":"Mol Endocrinol"},{"key":"R56-1-20210130","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/sonc.2002.37362","article-title":"Rationale for a phase III study of erythropoietin as a neurocognitive protectant in patients with lung cancer receiving prophylactic cranial irradiation.","volume":"29","author":"Senzer","year":"2002","journal-title":"Semin Oncol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006982-200701000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:19:42Z","timestamp":1786033182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006982-200701000-00001"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/01.iae.0000244659.62202.ee","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}